IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women

The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.